GLP1R and chronic kidney disease: The efficacy and safety of survodutide, a GLP-1 dual receptor agonist, in people with a BMI ≥ 27 kg/m2 was tested in 387 individuals (aged 18–75 years, BMI ≥ 27 kg/m2, without DM and with no CKD) who were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide (0.6, 2.4, 3.6, or 4.8 mg) or placebo for 46 weeks (20-week dose escalation; 26-week dose maintenance).